U.S. pharma giant copyright scrapped two experimental weight loss products previous year—a once-daily pill, lotiglipron, on account of elevated liver enzymes plus a 2 times-day by day tablet, danuglipron, as a consequence of robust side effects—but CEO Albert Bourla has explained the company is decided to “Engage in and get” inside the weig